Proton Pump Inhibitors Are Associated with Reduced Incidence of Dysplasia in Barrett's Esophagus

BACKGROUND AND AIMS:Esophageal acid exposure is important in the pathogenesis of Barrett's esophagus (BE), and possibly in the progression of BE to dysplasia and carcinoma. The aim of this study is to compare the development of dysplasia in BE patients treated with or without proton pump inhibitor (PPI) or histamine 2-receptor antagonist (H2RA).METHODS:We analyzed prospectively collected data by a single endoscopist on patients with BE in a VA (Veterans Affairs) setting over a 20-yr time period (1981–2000). A pathologist used standard criteria to diagnose BE/dysplasia. Pharmacy information after 1994 was retrieved from a computerized database, and from research files for the period before that. The receipt and the duration of H2RA and/or PPI use was compared between those with and without dysplasia. The incidence of dysplasia was examined in a Kaplan–Meier survival analysis stratified by PPI treatment status, and the risk of dysplasia was examined in a Cox multiple regression analysis controlling for demographic features, length of BE, and the year of BE diagnosis.RESULTS:We analyzed data for 236 unique veteran patients with a mean age at BE diagnosis of 61.5 yr, 86% Caucasian, and 98% male. During 1,170 patient-yr of follow-up, 56 patients developed dysplasia giving an annual incidence rate of 4.7%. Of those, 14 had high-grade dysplasia. The cumulative incidence of dysplasia was significantly lower among patients who received PPI after BE diagnosis than in those who received no therapy or H2RA; log rank test (p < 0.001). Furthermore, among those on PPIs, a longer duration of use was associated with less frequent occurrence of dysplasia. In multivariate analysis, the use of PPI after BE diagnosis was independently associated with reduced risk of dysplasia, hazards ratio: 0.25 (95% CI 0.13–0.47), p < 0.0001. Longer segments of BE and Caucasian race were other independent risk factors for developing dysplasia. In general, similar findings were observed when only cases with high-grade dysplasia were analyzed.CONCLUSIONS:These results indicate that PPI therapy is associated with a significant reduction in the risk of developing dysplasia in patients with BE. However, more studies are required to confirm this finding.

[1]  N. Shaheen,et al.  Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis , 2003, American Journal of Gastroenterology.

[2]  P. Parrilla,et al.  Long-Term Results of a Randomized Prospective Study Comparing Medical and Surgical Treatment of Barrett’s Esophagus , 2003, Annals of surgery.

[3]  A. Bhattacharyya,et al.  Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett’s oesophagus , 2003, Gut.

[4]  J. Devière,et al.  Long-term Follow-Up and Factors Predictive of Recurrence in Barrett's Esophagus Treated by Argon Plasma Coagulation and Acid Suppression , 2002, Endoscopy.

[5]  A. Sonnenberg,et al.  Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma , 2002, American Journal of Gastroenterology.

[6]  J. Goldblum,et al.  Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation , 2002, American Journal of Gastroenterology.

[7]  A. Csendes,et al.  Dysplasia and Adenocarcinoma After Classic Antireflux Surgery in Patients With Barrett’s Esophagus: The Need for Long-Term Subjective and Objective Follow-Up , 2002, Annals of surgery.

[8]  Dennis M. Riehle,et al.  Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. , 2001, Gastroenterology.

[9]  R. Sampliner,et al.  Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. , 2001, JAMA.

[10]  E. Montgomery,et al.  Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. , 2001, Human pathology.

[11]  M. Omary,et al.  Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. , 2000, Gastroenterology.

[12]  E. Kuipers,et al.  Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study , 1999, Gut.

[13]  A. Bhattacharyya,et al.  Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. , 1999, Gastrointestinal endoscopy.

[14]  N. Talley,et al.  Regression of Barrett's esophagus: the role of acid suppression, surgery, and ablative methods. , 1999, Gastrointestinal endoscopy.

[15]  R. Fitzgerald,et al.  Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. , 1999, Gastroenterology.

[16]  A. Bhattacharyya,et al.  Laser and multipolar electrocoagulation ablation of early Barrett's adenocarcinoma: long-term follow-up. , 1999, Gastrointestinal endoscopy.

[17]  A. Lindgren,et al.  Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. , 1999, The New England journal of medicine.

[18]  A. Bhattacharyya,et al.  Squamous Islands in Barrett's Esophagus: What Lies Underneath? , 1998, American Journal of Gastroenterology.

[19]  J. Reynolds,et al.  Expression of p53, PCNA, and C-erbB-2 in Barrett's Metaplasia and Adenocarcinoma , 1997, Digestive Diseases and Sciences.

[20]  A. Bhattacharyya,et al.  Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. , 1997, The American journal of gastroenterology.

[21]  D. Bagchi,et al.  Protection Against Chemically-Induced Oxidative Gastrointestinal Tissue Injury in Rats by Bismuth Salts , 1997, Digestive Diseases and Sciences.

[22]  R. Sampliner,et al.  Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. , 1997, The American journal of gastroenterology.

[23]  R. Cherian,et al.  Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. , 1997, The American journal of gastroenterology.

[24]  A. Bhattacharyya,et al.  Intestinal metaplasia of the gastric cardia. , 1997, The American journal of gastroenterology.

[25]  G. Lapertosa,et al.  Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. , 1996, Gastrointestinal endoscopy.

[26]  A. Pilotto,et al.  A comparison of five maintenance therapies for reflux esophagitis. , 1995, The New England journal of medicine.

[27]  J. Jankowski,et al.  Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: Biological and clinical variables , 1995, International journal of cancer.

[28]  R. Sampliner.  Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. , 1994, The American journal of gastroenterology.

[29]  R. Koehler,et al.  Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. , 1994, Gastroenterology.

[30]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[31]  D. Ransohoff,et al.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. , 1983, Human pathology.

[32]  R. Orlando.  Mechanisms of epithelial injury and inflammation in gastrointestinal diseases. , 2002, Reviews in gastroenterological disorders.

[33]  R. Sampliner,et al.  Impact of esophageal acid exposure on the endoscopic reversal of Barrett's esophagus (BE) , 2000, American Journal of Gastroenterology.